Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson’s disease

Kahana, Meygal; Weizman, Abraham; Gabay, Martín; Loboda, Yelena; Segal-Gavish, Hadar; Gavish, Avishai; Barhum, Yael; Offen, D.; Finberg, J. P. M.; Allon, Nahum; Gavish, Moshe

doi:10.1038/s41380-020-0742-4

Cited by 48 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary building blocks for liposomes are phosphatidylcholines derived from soybeans or eggs, with an established impact on brain delivery [ 27 , 28 , 29 ]. Additionally, cholesterol is typically added to increase membrane rigidity and prevent payload leakage [ 27 , 28 , 29 , 30 , 31 , 32 ]. The addition of surfactants, such as polysorbate 80 improves entrapment stability compared to the surfactant-free vesicles [ 32 ].…”

Section: Formulation-related Considerationsmentioning

confidence: 99%

“…Several techniques could be used to prepare lipid nanoparticles, including high-pressure homogenization (HPH) [ 25 , 34 , 36 , 38 , 40 , 44 ], thin film hydration followed by the sonication or filtration of liposomes [ 28 , 29 , 30 , 54 ], a combination of homogenization and sonication [ 46 , 47 ] or solvent-emulsification and evaporation techniques [ 45 ]. The physical and chemical complexity of the laboratory-scale prepared formulations is one of the facets that affect the scale-up of lipid nanoparticles, leading to difficulties in ensuring good stability during the shelf life [ 25 ].…”

Section: Formulation-related Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

et al. 2023

View full text Add to dashboard Cite

Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery across the blood–brain barrier (BBB). The growing availability of innovative excipients/ligands allowing improved brain targeting and controlled drug release makes the lipid nanocarriers a reasonable choice to overcome the factors impeding drug delivery through the BBB. However, a wide variety of methods, study designs and experimental conditions utilized in the literature hinder their systematic comparison, and thus slows the advances in brain-targeting by lipid-based nanoparticles. This review provides an overview of the methods most commonly utilized during the preclinical testing of liposomes, nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers intended for the treatment of various CNS disorders via the parenteral route. In order to fully elucidate the structure, stability, safety profiles, biodistribution, metabolism, pharmacokinetics and immunological effects of such lipid-based nanoparticles, a transdisciplinary approach to preclinical characterization is mandatory, covering a comprehensive set of physical, chemical, in vitro and in vivo biological testing.

show abstract

Section: Formulation-related Considerationsmentioning

confidence: 99%

Section: Formulation-related Considerationsmentioning

confidence: 99%

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…APP-targeted liposomes injected with dopamine (800 μg/kg) resulted in a substantial increase of striatal DA in amphetamine-treated mice within 5 min. The enhanced striatal DA content was observed in circulation 3 h post-administration, representing the sustained release of DA from the liposomes [ 123 ].…”

Section: Liposomal Approaches To Parkinson's Diseasementioning

confidence: 99%

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Pandian

Vijayakumar

Murugesan³

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…Similarly, Lopalco et al (2018) [ 142 ] functionalized DA-loaded liposomes with transferrin, a hydrophilic carrier that regulates the extracellular iron level in human fluid and whose receptor has been targeted for improving the BBB transport of drugs [ 143 ]. Other surface functionalization approaches have included the use of the amyloid precursor protein [ 144 ] and virus glycoproteins [ 145 ], among others [ 146 ].…”

Section: Controlled Drug Delivery On Parkinson’s Diseasementioning

confidence: 99%

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Padilla-Godínez

Ruiz-Ortega

Guerra-Crespo

2022

Cells

View full text Add to dashboard Cite

The complexity and overall burden of Parkinson’s disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.

show abstract

Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson’s disease

Cited by 48 publications

References 25 publications

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Contact Info

Product

Resources

About